The Trump administration is reportedly considering a way to ease Medicare and Medicaid into covering GLP-1 drugs like Ozempic ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

If a new experiment pans out, Medicaid and Medicare could begin covering the costly weight-loss drugs that price out many ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of ...

The Trump administration is planning a five-year test allowing states to cover weight-loss drugs like Ozempic and Wegovy ...

At a time when 45% of American women face significant barriers to reproductive care, Twentyeight Health is a telemedicine ...